Investigating the Role of Sotagliflozin in Cardiovascular Event Management

Introduction: Cardiovascular Disease (CVD) remains a leading cause of mortality worldwide, necessitating ongoing research into novel therapeutic approaches. Sotagliflozin, a dual inhibitor of Sodium-Glucose Cotransporter type 1 and type 2 (SGLT1 and SGLT2), has emerged as a promising agent for managing CVD. This review comprehensively examines the cardiovascular benefits of sotagliflozin, focusing on its mechanism of action, effects on glycemic control, weight management, blood pressure regulation, and overall cardiovascular outcomes. Methods: A thorough analysis of key clinical trials evaluating the efficacy and safety of sotagliflozin in patients with Type 2 Diabetes Mellitus (T2DM) and Heart Failure (HF), both with and without a history of Atherosclerotic Cardiovascular Disease (ASCVD), was conducted. Results: Sotagliflozin demonstrates significant potential in reducing Major Adverse Cardiovascular Events (MACE), hospitalizations due to heart failure, and cardiovascular mortality, especially in patients with T2DM and heart failure. Its dual SGLT1/SGLT2 inhibition may offer additional therapeutic advantages beyond those of selective SGLT2 inhibitors. Discussion: Notably, early initiation post-hospitalization and efficacy across different ejection fraction categories indicate a wider clinical application. However, the need for further studies remains, particularly to validate the added value of SGLT1 inhibition and to monitor for adverse effects such as gastrointestinal disturbances and hypoglycemia Conclusion: This review underscores the evolving role of sotagliflozin as a promising therapeutic option for CVD management. While its potential to revolutionize treatment and improve patient outcomes is evident, challenges such as adverse effects and drug interactions must be considered for optimal clinical use.